Last reviewed · How we verify
Statin plus niacin ER/laropiprant
A combination therapy that lowers LDL cholesterol via statin action while niacin ER/laropiprant raises HDL cholesterol and reduces triglycerides, with laropiprant blocking prostaglandin D2 receptors to reduce niacin-induced flushing.
A combination therapy that lowers LDL cholesterol via statin action while niacin ER/laropiprant raises HDL cholesterol and reduces triglycerides, with laropiprant blocking prostaglandin D2 receptors to reduce niacin-induced flushing. Used for Dyslipidemia and cardiovascular risk reduction in patients requiring statin and niacin therapy.
At a glance
| Generic name | Statin plus niacin ER/laropiprant |
|---|---|
| Sponsor | University of Ioannina |
| Drug class | Statin combined with niacin ER and DP1 antagonist |
| Target | HMG-CoA reductase (statin component); GPR109A/PUMA-G (niacin component); DP1 receptor (laropiprant component) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Statins inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis and LDL levels. Niacin (nicotinic acid) increases HDL and decreases triglycerides through multiple mechanisms including inhibition of hepatic VLDL production. Laropiprant is a selective antagonist of the prostaglandin D2 receptor (DP1), which mitigates the vasodilatory flushing side effect commonly associated with niacin therapy.
Approved indications
- Dyslipidemia and cardiovascular risk reduction in patients requiring statin and niacin therapy
Common side effects
- Flushing
- Myalgia
- Elevated liver enzymes
- Hyperuricemia
- Gastrointestinal upset
Key clinical trials
- The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients (PHASE4)
- Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069) (PHASE3)
- Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) (PHASE3)
- Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (PHASE3)
- Niacin/Laropiprant and Endothelial Function (PHASE4)
- Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Statin plus niacin ER/laropiprant CI brief — competitive landscape report
- Statin plus niacin ER/laropiprant updates RSS · CI watch RSS
- University of Ioannina portfolio CI